» Articles » PMID: 29289511

Opening of Voltage Dependent Anion Channels Promotes Reactive Oxygen Species Generation, Mitochondrial Dysfunction and Cell Death in Cancer Cells

Overview
Date 2018 Jan 1
PMID 29289511
Citations 89
Authors
Affiliations
Soon will be listed here.
Abstract

Enhancement of aerobic glycolysis and suppression of mitochondrial metabolism characterize the pro-proliferative Warburg phenotype of cancer cells. High free tubulin in cancer cells closes voltage dependent anion channels (VDAC) to decrease mitochondrial membrane potential (ΔΨ), an effect antagonized by erastin, the canonical promotor of ferroptosis. Previously, we identified six compounds (X1-X6) that also block tubulin-dependent mitochondrial depolarization. Here, we hypothesized that VDAC opening after erastin and X1-X6 increases mitochondrial metabolism and reactive oxygen species (ROS) formation, leading to ROS-dependent mitochondrial dysfunction, bioenergetic failure and cell death. Accordingly, we characterized erastin and the two most potent structurally unrelated lead compounds, X1 and X4, on ROS formation, mitochondrial function and cell viability. Erastin, X1 and X4 increased ΔΨ followed closely by an increase in mitochondrial ROS generation within 30-60 min. Subsequently, mitochondria began to depolarize after an hour or longer indicative of mitochondrial dysfunction. N-acetylcysteine (NAC, glutathione precursor and ROS scavenger) and MitoQ (mitochondrially targeted antioxidant) blocked increased ROS formation after X1 and prevented mitochondrial dysfunction. Erastin, X1 and X4 selectively promoted cell killing in HepG2 and Huh7 human hepatocarcinoma cells compared to primary rat hepatocytes. X1 and X4-dependent cell death was blocked by NAC. These results suggest that ferroptosis induced by erastin and our erastin-like lead compounds was caused by VDAC opening, leading to increased ΔΨ, mitochondrial ROS generation and oxidative stress-induced cell death.

Citing Articles

Metabolic consequences of erastin-induced ferroptosis in human ovarian cancer cells: an untargeted metabolomics study.

Kirkwood-Donelson K, Jarmusch A, Bortner C, Merrick B, Sinha B Front Mol Biosci. 2025; 11:1520876.

PMID: 39902375 PMC: 11788483. DOI: 10.3389/fmolb.2024.1520876.


Mitochondria as multifaceted regulators of ferroptosis.

Guo J, Zhou Y, Liu D, Wang M, Wu Y, Tang D Life Metab. 2025; 1(2):134-148.

PMID: 39872359 PMC: 11749789. DOI: 10.1093/lifemeta/loac035.


Ferroptosis and pyroptosis are connected through autophagy: a new perspective of overcoming drug resistance.

Zhao P, Yin S, Qiu Y, Sun C, Yu H Mol Cancer. 2025; 24(1):23.

PMID: 39825385 PMC: 11740669. DOI: 10.1186/s12943-024-02217-2.


Facts, Dogmas, and Unknowns About Mitochondrial Reactive Oxygen Species in Cancer.

Junco M, Ventura C, Santiago Valtierra F, Maldonado E Antioxidants (Basel). 2025; 13(12.

PMID: 39765891 PMC: 11673973. DOI: 10.3390/antiox13121563.


PGC1α is a key regulator of erastin-induced mitochondrial dysfunction during ferroptotic cell death.

Seok B, Park E, Park Y, Kwon H, Chung S BMB Rep. 2024; 58(2):89-94.

PMID: 39681411 PMC: 11875744.


References
1.
Warburg O . On the origin of cancer cells. Science. 1956; 123(3191):309-14. DOI: 10.1126/science.123.3191.309. View

2.
Nakashima R, Paggi M, Pedersen P . Contributions of glycolysis and oxidative phosphorylation to adenosine 5'-triphosphate production in AS-30D hepatoma cells. Cancer Res. 1984; 44(12 Pt 1):5702-6. View

3.
Bonnet S, Archer S, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R . A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell. 2007; 11(1):37-51. DOI: 10.1016/j.ccr.2006.10.020. View

4.
Maldonado E, Lemasters J . Warburg revisited: regulation of mitochondrial metabolism by voltage-dependent anion channels in cancer cells. J Pharmacol Exp Ther. 2012; 342(3):637-41. PMC: 3422523. DOI: 10.1124/jpet.112.192153. View

5.
Ewald F, Norz D, Grottke A, Bach J, Herzberger C, Hofmann B . Vertical Targeting of AKT and mTOR as Well as Dual Targeting of AKT and MEK Signaling Is Synergistic in Hepatocellular Carcinoma. J Cancer. 2015; 6(12):1195-205. PMC: 4622849. DOI: 10.7150/jca.12452. View